BIB Seed Capital is involved in commecial exploitation of the scientific and technological achievements of Polish scientists, promotion of the transfer of technologies from Polish scientific units to small and medium-sized companies that operate in Poland.
Projects related to obtaining specialized enzymes and hormones, development of bioinformatics products and services.
Projects related to obtaining specialized chemical substances, including catalysts, preparing documentation as well as obtaining and production of generic medicines, specialized feed components, or plant care substances.
spanning multiple fields
that are realized at the edge of medicine, biology, chemistry, physics and informatics.
Our objective is building an effective cooperation model between the spheres of science and business, leading to long-term mutual benefits.
BIB Seed Capital uses various methods of acquiring. Among others we cooperate with:
- university and PAN partners;
- cooperate with technology parks;
- actively monitor of scientific environments for R&D projects;
SDG, November 2008
SDG (Software Development Group) is a company operating in the IT field, whose domain is modern technologies and creating functional software.
The company works on the development and perfection of applications, which are to be easy and convenient to use, customized to each client's individual needs. The most attention is paid to mobile applications using a long list of modern technologies for it. SDG realizes its projects using the SDLC (System Development Life Cycle) methodology, which is about creating IT systems through such phases as: client's need analysis, creating the system design and application.
SDG makes use of outsourcing in tis operations, which is a modern management strategy, which is about giving an external partner tasks that are not directly related to the general operation of the company. Thanks to that SDG is able to complete projects of various scales. The main goal of Software Development Group is creating software that eases efficient work, ensures good workflow and security.
- Development and distribution of Mobile Assistant Lite - an application that eases the flow of information and allowing for the creation of messages with a custom signature, efficient message management and a recipient base.
- Creation and marketing of Machine State Control System - an application for fault and delay diagnostics in industrial machines.
- Introduction of software for a unique marketing system known as BlueCasting.
A possibility of reaching an important position in this still underdeveloped and undersaturated market of specialist software development.
Neuralia, September 2008
Neuralia is a company operating in the marketing industry that uses modern neuroscientific achievements that have already been approved in highly developed countries. They offer professional services in the field of neuromarketing and quality research according to very effective custom-designed methods. Neuralia also offers consulting in the field of effective use of neuroscience in any business.
The company was created by marketing specialists, as well as scientists, psychology and neuroscience professionals. That is why the experience of the experts allowed for the creation of custom, effective methods and research tools.
Neuromarketing services offered by Neuralia work on the basis of using the knowledge about human behavior and measurement tools used in psychophysiological studies. The company uses unique mixes of various methods for measurement, in the research it uses such devices:
- GSR - (Gelvanic Skin Response) - measures organism responses,
- EMG - electromyogram - measures tension of facial muscles,
- ETR - eye tracker - device that follows the movement of the eyeball and measures the customer's focus.
During a study, the respondents usually watch videos, presentations or websites of a particular company. Thanks to that the client gets the full data about the reactions of the studied persons, which eases decision making related to introducing a product on the market and its marketing campaign.
Thanks to advanced research technologies the experts working for Neuralia are able to answer many questions about the brand and the product, explain issues that were previously only guesses.
- Development and selling of neuroADS - a unique study about the efficiency of ads and posters using the eye tracker.
- Creation and distribution of neuroDeclaration - an innovative method of studying visible and hidden consumer preferences.
- Introduction and order handling of neuroUsability - a unique evaluation system of usability of websites.
A possibility of working out a recognizable brand offering innovative and highly effective products in the lucrative and prestigious marketing services industry.
Medicalgorithmics, June 2008
Medicalgorithmics operates on the basis of using advanced algorithms for signal and medical data analysis. The company not only researches specialist systems, but also the production and distribution of modern technical devices. Medicalgorithmics specializes in heart examination technologies. The team consists of people with widespread knowledge and experience in designing software for hospital applications, electrical engineering, physics and technology transfer.
Among the devices created by the company is the Pocket ECG - a unique device that allows for a real-time supervised remote heart examination. It is a one-of-a-kind system, whose key element is a smartphone-like device - a microcomputer with a touch screen, acting as a telephone with GSM and Bluetooth modules. Pocket ECG is the only device in the world that analyzes and transfers the whole ECG signal in real time, as well as a detailed description to a specialized doctor or a monitoring center.
Another technology developed by Medicalgorithmics is the Coperniqs - a cardiac muscle visualization kit and a tool for the analysis of variables that are important in invasive heart operations, such as ablations. Moreover, the company is working on another device called HeartSounds, which examines blood flow in a patient's heart. It is a technology that can revolutionize the market of initial diagnostics of heart defects, as it is a combination of the classic stethoscope examination and a costly ultrasound examination (so-called ECHO of the heart).
- Selling of cardio monitor software (EMTEL).
- Contract for 50 pocket-ECGs for the Cardiology Institute.
- Acquiring of a certificate allowing for the sale of pocket-ECG on the American market.
- Advanced negotiations with the United States recipients.
A possibility of sale of unique products, working out a recognizable brand on the lucrative and prestigious medical device market.
AdvaChemLab, June 2008
AdvaChemLab is a company that is working on developing technologies of obtaining highly specialized chemical products, which include: catalysts and asymmetric synthesis agents as well as biologically active products (active substances used to obtain medicines and cosmetics).
The main goal of the company is achieving the top position among chemical laboratories that produce highly processed chemical substances, as well as directing its operations into the cosmetics and pharmaceutical industries. AdvaChemLab has a chemical laboratory equipped with a rich set of agents and appropriate research tools. Thanks to that it has the possibility to design substances of desired activity and their synthesis. Through its activity Advachemlab has a good position when it comes to high demand for catalysts and pharmacological substances. Currently, the company is focusing on designing and introducing two of its own products (a catalyst and a new medicine) and advanced (bio)organic synthesis. It is also interested in substances that are important for the functioning of selected enzymes related to the biosynthesis of cholesterol in humans.
The company not only delivers highly specialist chemical agents, but also conducts search for new substances with antifungal activity and substances accelerating the regeneration of the skin, including healing of wounds (floretamid).
- Unique possibilities in diverging substances through distillation
- Experience in planning and conducting advanced chemical syntheses
- Portfolio of 20 substances with a potential antifungal application
A possibility of taking an important position in the young, dynamic and unshaped market of specialized chemical laboratories.
Mitoda, March 2008
The Mitoda company specializes in modern IT solutions supporting the functioning of enterprises and institutions. It is working on development and distribution of software dedicated to creation and management of Public Information Bulletins (BIP) as well as introduction of innovative tools of mobile marketing.
Public Information Bulletin (BIP) is a website system meant for the universal and free-of-charge access to public information, which every citizen has a right to. According to a bill from September 6, 2001, all institutions (with few exceptions) are obliged to make appropriate information about themselves accessible.
Thanks to cooperation with SDG, Mitoda can also offer Bluecasting, a mobile marketing system that makes use of the Bluetooth technology. Thanks to that, it is possible to introduce a cheap and effective advertising campaign. Proper software makes it possible to customize the system to the client's individual needs. The main product of the cooperation with SDG is also Mobile Assistant Pro - an application that eases the flow of information in companies.
- Development of software meeting the requirements of the current orders of the Interior and Administration Ministry.
- Distribution of Mobile Assistant Pro.
- Working on the Public Information Bulletins.
- Hosting services for Public Information Bulletins.
Filling of an interesting niche related to access to public information, which all public entities are obliged to do.
Genovum, January 2008
Genovum is an innovative company operating in the industries of information technology, biotechnology and healthcare. Its operation is based on applying bioinformatics methods to aid the sequencing of genomes, creating new enzymes and new simple organisms with healing properties. The company is focused on using bacteriophages (bacterial viruses which attack bacteria) as a diet supplement directed against bacteria causing the peptic ulcer disease - Helicobacter pylori. The product has a good chance of a commercial success, because conditions caused by helicobacter pylori affect a large portion of the population.
Genovum has achieved such things as: high places in international protein structure prediction competitions, contact with many European units and cooperation in European projects, preparation for a large project as part of a consortium of Polish biotechnology companies and a portfolio of 20 new enzymes.
The unique technology proposed by Genovum allows for the search of environmental enzymes with desired properties and optimization of enzymes for biotechnological and medical purposes. Moreover, there is a possibility of analysis and optimization of simple organisms such as phages, in order to increase the efficiency of treating bacterial infections.
- Good success in international protein structure prediction competitions.
- Contact with many units in Europe and cooperation as part of European projects.
- Preparation for a large project as part of the consortium of Polish biotechnology companies.
- Portfolio of 20 new enzymes.
The unique technology allows for the search of environmental enzymes with desired properties and optimization of enzymes for biotechnological and medical purposes. Moreover, there is a possibility of analysis and optimization of simple organisms such as phages, in order to increase the efficiency of treating bacterial infections.
Proteon Pharmaceuticals, January 2008
Proteon Pharmaceuticals specializes in testing the toxicity of medicines and chemical compounds. The company is working on introduction of highly advanced technologies, which improve and speed up the process of medicine research. The applied biotechnological methods for the evaluation of the influence of the tested substances, including potential medicines, on the immune system.
One of the technologies developed by Proteon Pharmaceuticals is the Fluorescent Cell Chip technology, which makes it possible to efficiently research the chemical ingredients and the analysis of defined biological activities. It allows for an evaluation of the safety of chemical substances by detecting their potential immunotoxicity, that is the negative influence on the human immune system. Moreover, the FCC is also used to detect the immunomodulating properties of the chemical substances. Such substances may become new anti-inflammatory, anti-allergic, immunosuppressive or anti-cancer drugs.
Proteon Pharmaceuticals can also offer a service based on searching through the so-called chemical libraries owned by pharmaceutical corporations, in order to find new chemical substances with the desired immunomodulating properties (desired influence on the immune system). Such actions are used by the leaders of the pharmaceutical industry in the process of designing new drugs.
- Perfection of the screening technology and transition to the production phase.
- Realization of common projects and screening of active substances with 3 companies (incl. 2 foreign ones).
- Preparation for signing of a contract with a large Polish pharmaceutical company.
The technology makes it possible to discover new medical substances with a potentially large demand. The company is operating in one of the most flexible industries in the world.
Professor of Chemistry, graduated from biotechnology studies at the Biology Department of UAM, in 2000 MBA (Georgia State University Atlanta and the Economic Academy in Poznań). In the years 2001-2002 he was awarded a shcholarship from the Foundation for Polish Science to study with Keiji Morokuma at the University of Emory in Atlanta. He studies molecular recognition and reaction mechanisms. He studies effects of fluorine atom introduction into chemical compounds; mechanisms of reactions catalysed by transition metal complexes.
In the years 2002-2003 he worked as a consultant in McKinsey & Co in Warsaw, where he participated in projects related to the telecommunications sector and energy carriers.
Since 2004 he has been involved in BioInfoBank. He was responsible for running the part of the company that was dedicated to investing in newly created innovative companies.
Thanks to his scientific and business experience, he can efficiently communicate with scientists and businessmen alike and has the knowledge and experience related to the needs of the commercial utilization of scientific research from the innovative solution creation stage by evaluating its commercial potential, formulating the product strategy, organizing an innovative company and its development.
Graduated from medical school in Berlin and later worked in San Diego, where he conducted bioinformatics research. In 200 he returned to Poland, where he conducted bioinformatics research in the International Institute of Molecular Biology. He has co- authored over 100 scientific papers.
He was the founder of BioInfoBank, as well as Instytut BioInfoBank, which conducts research in the field of bioinformatics. He organizes cooperation between researchers and businesses (he was, among others, the coordinator of the Center of Excellence CITech (Center for Innovative Technologies) which cooperated with scientific laboratories and bioinformatics enterprises).
He has realized and numerous projects of the European Commission-funded 5th, 6th and7th Program for the total value of over 20 million euro (including the budget of the European partners). His scientific and business experience allow L. Rychlewski to possess extensive knowledge on topics related to development and functioning of innovative bioinformatics enterprises in Poland.
BIB Seed Capital joint stock company with registered office in Poznań
Addres: ul. Święty Marcin 80/82/355, 61-809 Poznań, Poland
Responsible Entity: Sąd Rejonowy Poznań - Nowe Miasto i Wilda w Poznaniu, VIII Wydział Gospodarczy Krajowego Rejestru Sądowego
National Court Register: 0000379911
Vat Number (NIP): 9721156719
Share Capital: PLN 100 000
BIB Seed Capital is in the Poznań Regional Court enterprise registry, VIII WG KRS, no. 0000379911
BIB Seed Capital s.a.
ul. Św. Marcin 80/82 lok. 355
tel/fax: (+48 61) 852 49 46
NIP: 972 115 67 19